25,836 Shares in DaVita Inc. (NYSE:DVA) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new stake in shares of DaVita Inc. (NYSE:DVA) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 25,836 shares of the company’s stock, valued at approximately $3,864,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. SBI Securities Co. Ltd. bought a new position in shares of DaVita during the fourth quarter valued at $41,000. Quarry LP bought a new position in DaVita in the third quarter valued at approximately $60,000. Venturi Wealth Management LLC increased its holdings in DaVita by 59.8% in the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock valued at $61,000 after purchasing an additional 152 shares during the last quarter. Versant Capital Management Inc grew its holdings in DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after purchasing an additional 169 shares during the period. Finally, Blue Trust Inc. raised its position in shares of DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company’s stock worth $76,000 after purchasing an additional 131 shares during the period. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

Shares of NYSE:DVA opened at $151.30 on Thursday. The firm’s fifty day moving average is $157.96 and its 200-day moving average is $157.53. DaVita Inc. has a 52 week low of $125.64 and a 52 week high of $179.60. The firm has a market cap of $12.10 billion, a PE ratio of 14.09, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26.

DaVita (NYSE:DVA) last released its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Sell-side analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Ratings Changes

DVA has been the subject of a number of recent research reports. Barclays upped their price target on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. Cowen restated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. StockNews.com cut DaVita from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. Finally, Sanford C. Bernstein set a $184.00 target price on DaVita in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.